HIGHLIGHTS
- who: Silvia Ferrucci et al. from the 0122, Italy have published the article: Clinical Medicine, in the Journal: (JOURNAL)
- how: At baseline the following data were collected sex age at AD onset age at dupilumab initiation extrinsic/intrinsic status baseline total serum immunoglobulin (Ig)E baseline serum eosinophil count previous treatment with CsA (intolerance/ineffectiveness/contraindication) and concurrent use of systemic corticosteroids at baseline. The authors investigated anxiety and depression using HADS and the authors substantiated in accordance with a previous study by Cork et_al a significant reduction in anxiety and depression scores after dupilumab . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.